MoFo BioMeter - Vol. 3, Issue 1, March 2014 - Q4 and FY 2013 BioMeter Shows Rebound in Value for Late Stage Products and Strong Results Across All Stages of Development Regional Analysis Shows SF Leads But Others Are Close (and It’s Not Who You Think)

more+
less-
more+
less-

The full-year 2013 BioMeter analysis shows across-the-board increases in BioMeter value, with an average of $33.9 million for all transactions, up from approximately $21.2 million in 2012. Increases occurred for each stage of development, with the BioMeter for preclinical/discovery transactions averaging approximately $21.8 million in 2013, compared to approximately $10 million in 2012; the BioMeter value for Phase 1 products averaging approximately $40 million in 2013 compared to approximately $10 million in 2012; the BioMeter value for Phase 2 products increasing to approximately $47.4 million in 2013 from approximately $37.1 million in 2012; the BioMeter value for Phase 3 products increasing to approximately $46.2 million in 2013 from approximately $24.6 million in 2012; and the BioMeter value for approved products increasing to approximately $50.6 million in 2013 from approximately $27 million in 2012.

This data shows strength for sellers/licensors across all stages of the drug development spectrum. Indeed, the only reason that the overall average BioMeter did not jump more compared to 2012 is because of the mix of transactions. In 2013, preclinical/discovery transactions accounted for approximately 48% of transactions reporting up-front payments and reporting stage of development, compared to approximately 38% of transactions in 2012.

Please see full issue below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Pharmaceutical, Prescription Drugs

Published In: General Business Updates, Health Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »